Suppression of vaccine immunity by inflammatory monocytes

Journal of Immunology

Volumn 189, Issue 12, 2012, Pages 5612-5621

  Mitchell, Leah A ^a   Henderson, Angela J ^a   Dow, Steven W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MANIPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION; LYMPH NODE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; VACCINATION;

ANIMALS; CANCER VACCINES; CATIONS; CELL LINE, TUMOR; CELL MIGRATION INHIBITION; CYSTEINE; IMMUNE TOLERANCE; INFLAMMATION; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, CCR2; VACCINES, DNA;

EID: 84871109342     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202151     Document Type: Article

References (51)

1. Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
2. Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32.
3. Sharp, F. A., D. Ruane, B. Claass, E. Creagh, J. Harris, P. Malyala, M. Singh, D. T. O'Hagan, V. Pétrilli, J. Tschopp, et al. 2009. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 106: 870-875.
4. Mosca, F., E. Tritto, A. Muzzi, E. Monaci, F. Bagnoli, C. Iavarone, D. O'Hagan, R. Rappuoli, and E. De Gregorio. 2008. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA 105: 10501-10506.
5. Tritto, E., F. Mosca, and E. De Gregorio. 2009. Mechanism of action of licensed vaccine adjuvants. Vaccine 27: 3331-3334.
6. Randolph, G. J., V. Angeli, and M. A. Swartz. 2005. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5: 617-628. (Pubitemid 41113193)
7. Cheng, P., C. A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M. M. Bui, M. Ortiz, W. Nacken, C. Sorg, T. Vogl, et al. 2008. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205: 2235-2249.
8. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64: 6337-6343. (Pubitemid 39129439)
9. Martino, A., E. Badell, V. Abadie, V. Balloy, M. Chignard, M. Y. Mistou, B. Combadière, C. Combadière, and N. Winter. 2010. Mycobacterium bovis bacillus Calmette-Guérin vaccination mobilizes innate myeloid-derived suppressor cells restraining in vivo T cell priming via IL-1R-dependent nitric oxide production. J. Immunol. 184: 2038-2047.
10. Nakano, H., K. L. Lin, M. Yanagita, C. Charbonneau, D. N. Cook, T. Kakiuchi, and M. D. Gunn. 2009. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. Nat. Immunol. 10: 394-402.
11. Peters, W., M. Dupuis, and I. F. Charo. 2000. A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J. Immunol. 165: 7072-7077. (Pubitemid 32001181)
12. Dunay, I. R., R. A. Damatta, B. Fux, R. Presti, S. Greco, M. Colonna, and L. D. Sibley. 2008. Gr1(+) inflammatory monocytes are required for mucosal resistance to the pathogen Toxoplasma gondii. Immunity 29: 306-317.
13. Goodyear, A., A. Jones, R. Troyer, H. Bielefeldt-Ohmann, and S. Dow. 2010. Critical protective role for MCP-1 in pneumonic Burkholderia mallei infection. J. Immunol. 184: 1445-1454.
14. Netea, M. G., G. D. Brown, B. J. Kullberg, and N. A. Gow. 2008. An integrated model of the recognition of Candida albicans by the innate immune system. Nat. Rev. Microbiol. 6: 67-78. (Pubitemid 350286221)
15. Czuprynski, C. J., P. A. Campbell, and P. M. Henson. 1983. Killing of Listeria monocytogenes by human neutrophils and monocytes, but not by monocyte-derived macrophages. J. Reticuloendothel. Soc. 34: 29-44. (Pubitemid 13012981)
16. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176: 284-290. (Pubitemid 43023273)
17. Ostrand-Rosenberg, S., and P. Sinha. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182: 4499-4506.
18. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
19. Serafini, P., K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello. 2006. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203: 2691-2702. (Pubitemid 44833345)
20. Ko, J. S., A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. Rayman, L. Wood, J. Garcia, et al. 2009. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15: 2148-2157.
21. Song, X., D. Ye, B. Liu, J. Cui, X. Zhao, L. Yi, J. Liang, J. Song, Z. Zhang, and Q. Zhao. 2009. Combination of all-trans retinoic acid and a human papillomavirus therapeutic vaccine suppresses the number and function of immature myeloid cells and enhances antitumor immunity. Cancer Sci. 100: 334-340.
22. van Deventer, H. W., J. E. Burgents, Q. P. Wu, R. M. Woodford, W. J. Brickey, I. C. Allen, E. McElvania-Tekippe, J. S. Serody, and J. P. Ting. 2010. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res. 70: 10161-10169.
23. Hafeman, S., C. London, R. Elmslie, and S. Dow. 2010. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol. Immunother. 59: 441-452.
24. van Rooijen, N., and E. van Kesteren-Hendrikx. 2003. "In vivo" depletion of macrophages by liposome-mediated "suicide". Methods Enzymol. 373: 3-16.
25. Rehni, A. K., and T. G. Singh. 2012. Involvement of CCR-2 chemokine receptor activation in ischemic preconditioning and postconditioning of brain in mice. Cytokine 60: 83-89.
26. Rehni, A. K., and N. Singh. 2012. Ammonium pyrrolidine dithiocarbamate and RS 102895 attenuate opioid withdrawal in vivo and in vitro. Psychopharmacology (Berl.) 220: 427-438.
27. Dow, S. W., L. G. Fradkin, D. H. Liggitt, A. P. Willson, T. D. Heath, and T. A. Potter. 1999. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J. Immunol. 163: 1552-1561. (Pubitemid 29352779)
28. van Leyen, K., K. Arai, G. Jin, V. Kenyon, B. Gerstner, P. A. Rosenberg, T. R. Holman, and E. H. Lo. 2008. Novel lipoxygenase inhibitors as neuroprotective reagents. J. Neurosci. Res. 86: 904-909. (Pubitemid 351357770)
29. Hamilton, M. J., J. P. Banáth, V. Lam, N. E. Lepard, G. Krystal, and K. L. Bennewith. 2012. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice. Cancer Immunol. Immunother. 61: 643-654.
30. Zaks, K., M. Jordan, A. Guth, K. Sellins, R. Kedl, A. Izzo, C. Bosio, and S. Dow. 2006. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176: 7335-7345. (Pubitemid 43849034)
31. Qian, B. Z., J. Li, H. Zhang, T. Kitamura, J. Zhang, L. R. Campion, E. A. Kaiser, L. A. Snyder, and J. W. Pollard. 2011. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475: 222-225.
32. Volpe, S., E. Cameroni, B. Moepps, S. Thelen, T. Apuzzo, and M. Thelen. 2012. CCR2 acts as scavenger for CCL2 during monocyte chemotaxis. PLoS ONE 7: e37208.
33. Woo, J. I., H. Pan, S. Oh, D. J. Lim, and S. K. Moon. 2010. Spiral ligament fibrocyte-derived MCP-1/CCL2 contributes to inner ear inflammation secondary to nontypeable H. influenzae-induced otitis media. BMC Infect. Dis. 10: 314.
34. Mirzadegan, T., F. Diehl, B. Ebi, S. Bhakta, I. Polsky, D. McCarley, M. Mulkins, G. S.Weatherhead, J. M. Lapierre, J. Dankwardt, et al. 2000. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem. 275: 25562-25571.
35. Serafini, P., S. Mgebroff, K. Noonan, and I. Borrello. 2008. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68: 5439-5449.
36. Ding, Z. C., B. R. Blazar, A. L. Mellor, D. H. Munn, and G. Zhou. 2010. Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 115: 2397-2406.
37. Srivastava, M. K., P. Sinha, V. K. Clements, P. Rodriguez, and S. Ostrand- Rosenberg. 2010. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70: 68-77.
38. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
39. Highfill, S. L., P. C. Rodriguez, Q. Zhou, C. A. Goetz, B. H. Koehn, R. Veenstra, P. A. Taylor, A. Panoskaltsis-Mortari, J. S. Serody, D. H. Munn, et al. 2010. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116: 5738-5747.
40. Veltman, J. D., M. E. Lambers, M. van Nimwegen, R. W. Hendriks, H. C. Hoogsteden, J. G. Aerts, and J. P. Hegmans. 2010. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 10: 464.
41. Bunt, S. K., V. K. Clements, E. M. Hanson, P. Sinha, and S. Ostrand-Rosenberg. 2009. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85: 996-1004.
42. Bierie, B., and H. L. Moses. 2010. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev. 21: 49-59.
43. Shi, C., T. Jia, S. Mendez-Ferrer, T. M. Hohl, N. V. Serbina, L. Lipuma, I. Leiner, M. O. Li, P. S. Frenette, and E. G. Pamer. 2011. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 34: 590-601.
44. Fridlender, Z. G., G. Buchlis, V. Kapoor, G. Cheng, J. Sun, S. Singhal, M. C. Crisanti, L. C. Wang, D. Heitjan, L. A. Snyder, and S. M. Albelda. 2010. CCL2 blockade augments cancer immunotherapy. Cancer Res. 70: 109-118.
45. Tsuboi, N., Y. Yoshikai, S. Matsuo, T. Kikuchi, K. Iwami, Y. Nagai, O. Takeuchi, S. Akira, and T. Matsuguchi. 2002. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J. Immunol. 169: 2026-2033. (Pubitemid 34857667)
46. Muruve, D. A., V. Pétrilli, A. K. Zaiss, L. R. White, S. A. Clark, P. J. Ross, R. J. Parks, and J. Tschopp. 2008. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452: 103-107. (Pubitemid 351355095)
47. Yao, H., Y. Yang, K. J. Kim, C. Bethel-Brown, N. Gong, K. Funa, H. E. Gendelman, T. P. Su, J. Q. Wang, and S. Buch. 2010. Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood 115: 4951-4962.
48. Kindrachuk, J., H. Jenssen, M. Elliott, R. Townsend, A. Nijnik, S. F. Lee, V. Gerdts, L. A. Babiuk, S. A. Halperin, and R. E. Hancock. 2009. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27: 4662-4671.
49. Shahrara, S., S. R. Pickens, A. M. Mandelin, II, W. J. Karpus, Q. Huang, J. K. Kolls, and R. M. Pope. 2010. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J. Immunol. 184: 4479-4487.
50. Horuk, R. 2009. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8: 23-33.
51. Xia, M., and Z. Sui. 2009. Recent developments in CCR2 antagonists. Expert Opin. Ther. Pat. 19: 295-303.